HASBROUCK HEIGHTS, N.J., May 15, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2012. Nymox reported a net loss of $1,846,974, or $0.06 per share for the quarter ended March 31, 2012, compared to $4,431,091, or $0.14 per share for the quarter ended March 31, 2011. Net losses include stock-based compensation charges of $51,496 in the quarter ended March 31, 2012 and $3,583,258 in the comparative period in 2011. The decrease in net losses is attributable primarily to higher stock-based compensation charges in 2011 compared to 2012.
